News & Updates

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023 by

Use of antihypertensive medications does not appear to reduce the risk of all-cause mortality in patients with heart failure (HF) with preserved ejection fraction (HFpEF), reports a study presented at AHA 2023. However, treatment with antihypertensives can lower the risk of adverse cardiovascular (CV) outcomes regardless of the patient’s hypertension status.

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

20 Nov 2023

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023 by

Treatment with dapagliflozin results in a lower risk of worsening heart failure (HF) or cardiovascular death and improvements in symptoms among patients with HF and type 2 diabetes (T2D), with or without neuropathy, according to a study presented at AHA 2023. However, the beneficial effects of dapagliflozin appears more evident in those with neuropathy.

Dapagliflozin offers cardioprotection in HF patients with T2D

20 Nov 2023

Experts share essential updates on COVID-19 vaccines

20 Nov 2023 by

SARS-CoV-2 continues to evolve into newer variants. Post-Delta, these variants are generally more highly transmissible and immune-evasive, although not more virulent, said Dr Gregory Poland, Mary Lowell Leary Emeritus Professor of Medicine and director of Mayo Vaccine Research Group, Mayo Clinic in Rochester, Minnesota, US, at IDWeek 2023.

Experts share essential updates on COVID-19 vaccines

20 Nov 2023

Dementia risk heightened after stopping metformin treatment

18 Nov 2023 by

Metformin treatment discontinuation has been found to lead to increased incidence of dementia among older adults, and this association cannot be explained by changes in glucose control or insulin use.

Dementia risk heightened after stopping metformin treatment

18 Nov 2023

Torsemide as good as furosemide for treating de novo, chronic heart failure

18 Nov 2023

Among patients with heart failure (HF), those who have de novo HF have better outcomes than those who have worsening chronic HF status, but treatment with torsemide yields 12-month outcomes that are similar to that observed with furosemide regardless of HF type, according to a post hoc analysis of the TRANSFORM-HF trial.

Torsemide as good as furosemide for treating de novo, chronic heart failure

18 Nov 2023

COVID-19 vaccination during pregnancy protects babies against Omicron infection

17 Nov 2023 by

Receiving an mRNA vaccine during pregnancy appears to put newborns at low risk of SARS-CoV-2 infection with the Omicron variant through 6 months of age, according to a study from Singapore.

COVID-19 vaccination during pregnancy protects babies against Omicron infection

17 Nov 2023

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

17 Nov 2023 by

Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

17 Nov 2023

Biologic therapy improves life quality of asthmatic children

17 Nov 2023 by

Treatment with biologic agents results in significant improvements in both function and quality of life among paediatric patients with moderate-to-severe asthma, according to a recent study presented at ACAAI 2023.

Biologic therapy improves life quality of asthmatic children

17 Nov 2023

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

A first-in-human randomized, phase I study has provided evidence to support the clinical development of RG6346 as a therapeutic regimen for chronic hepatitis B virus (HBV) infection (CHB), with the goal of sustained hepatitis B surface antigen (HBsAg) loss in CHB patients.

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

17 Nov 2023

Lepodisiran lowers lipoprotein(a) concentrations in early trial

17 Nov 2023

Treatment with lepodisiran yields dose-dependent and durable reductions in serum lipoprotein(a) levels while being well tolerated, according to the results of a phase I trial.

Lepodisiran lowers lipoprotein(a) concentrations in early trial

17 Nov 2023

News & Updates

Filter by Specialty:

Specialty:

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Antihypertensives reduce adverse CV outcomes, but not death, in HFpEF patients

Dapagliflozin offers cardioprotection in HF patients with T2D

Dapagliflozin offers cardioprotection in HF patients with T2D

Experts share essential updates on COVID-19 vaccines

Experts share essential updates on COVID-19 vaccines

Dementia risk heightened after stopping metformin treatment

Dementia risk heightened after stopping metformin treatment

Torsemide as good as furosemide for treating de novo, chronic heart failure

Torsemide as good as furosemide for treating de novo, chronic heart failure

COVID-19 vaccination during pregnancy protects babies against Omicron infection

COVID-19 vaccination during pregnancy protects babies against Omicron infection

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients

Biologic therapy improves life quality of asthmatic children

Biologic therapy improves life quality of asthmatic children

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

RNAi agent RG6346 shows promise for treatment of chronic HBV infection

Lepodisiran lowers lipoprotein(a) concentrations in early trial

Lepodisiran lowers lipoprotein(a) concentrations in early trial